For more information, please visit the EACR 2025 website. Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune ...

Emily Bodnar, an analyst at H.C. Wainwright, raised her price target for Purple Biotech Ltd. (NASDAQ:PPBT) from $33 to $34 ...

Purple Biotech shares are trading lower by 27.7% during Tuesday's session. The company announced a $2.8 million offering. Memorial Day Special: Access your full investing command center with ...

An update from Purple Biotech ( (PPBT)) is now available. On April 22, 2025, Purple Biotech Ltd. held its Annual General Meeting of Shareholders, where several proposals were voted on. The ...

Purple Biotech (PPBT) has released an update. Purple Biotech Ltd., a clinical-stage bio-pharmaceutical company, is set to present its groundbreaking CAPTN-3 platform at the EORTC-NCI-AACR Symposium.

26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal ...

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology ...

creating a vibrant purple color. Martin and her colleagues published the first results of their research in 2008 in an article in Nature Biotechnology. The results were “stunning,” she said.

Purple Biotech shares are trading lower by 11.5% during Monday's session. The company announced the exercise of warrants for $2 million gross proceeds. Unlock your all-in-one trading dashboard ...

Purple Biotech is adding Immunorizon’s tri-specific antibodies to its paint palette in an acquisition that could reach $100 million. The M&A deal, announced Thursday morning, will see privately ...